Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Medicover misses revenue growth in Q3 and warns of a slowdown
Medicover reports revenue growth of 12.1% (organic 12.4%) in the third quarter of 2025, below consensus expectations of 14.5% (organic 14.3%). The Healthcare Services segment grew 9.6% with strong gains in Poland and Romania; India showed a reported decline of -1.5% due to currency effects. Diagnostic Services increased by 17.8%, lab test volumes rose 17.4%, and the adjusted EBITDA margin improved to 17.2%. Acquisitions supported revenue and margins, and leverage fell to 3.2x. Management expects a slowdown from Q4 for several quarters because of more cautious consumer behaviour and the ramp-up of two new hospitals in India. » More on de.investing.com
Medicover increases revenue and margin in the second quarter of 2025
Medicover recorded revenue growth of 17.1% in the second quarter of 2025 and improved its adjusted EBITDA margin to 16.9%. The main growth drivers were the Healthcare Services division and business in Poland, while new units in India and Romania continued to weigh on margins. Net debt increased slightly due to acquisitions, but management expects a relaxation in the second half of the year. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 570.8m | 4.60% |
| Gross profit | 141.2m | 0.59% |
| Net profit | 25.7m | 30.32% |
| EBITDA | 101.9m | 3.34% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.56bn |
Number of shares | 151.97m |
52-week high/low | €25.52 - €16.09 |
Dividend yield | 0.08% |
Dividends TTM | €0.0184 |
Beta | 1.51 |
P/E ratio | 39.73 |
PEG ratio | 1.28 |
P/B ratio | 6.60 |
P/S ratio | 1.46 |
Company profile
Medicover AB (publ) provides healthcare and diagnostic services in Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It operates through two segment, Healthcare Services and Diagnostic Services. The company's diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company operates 97 clinical laboratories, 733 blood-drawing points, and 26 clinics in 10 countries; and 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. It serves corporate and private customers, and patients, as well as public payers. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.
| Name | MEDICOVER AB |
| CEO | John Paul Stubbington |
| Headquarters | Stockholm,
ab USA |
| Website | |
| IPO | 12/11/2020 |
| Employees | 49,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
London Stock Exchange | 0RPS.L |
Sto | MCOV-B.ST |
Pnk | MCVEF |
Frankfurt | 5M0B.F |
Düsseldorf | 5M0B.DU |
London | 0RPS.L |
Stockholm | MCOV B.ST |
München | 5M0B.MU |